Clarivate, a global leader in connecting people and organisations to intelligence they can trust to transform their world, has announced the release of its new report, Making gene therapy work for patients, payers, regulators and developers: Five key trends in gene therapy approvals and access. The report explores the challenges and triumphs of gene therapy, with an eye on how developers are addressing risk and the need for multiple modalities and how payers are exploring alternative payment methods.
Nearly 50 years since scientists first proposed the idea of modifying defective genes to treat genetic illnesses, the gene therapy revolution has evolved to include treatments that offer the promise of better health outcomes and/or quality of life for patients with rare diseases. Yet, there is a major gap between the needs of developers and payers faced with absorbing the costs of a wave of medical innovation elsewhere. Similarly, regulators are wrestling with policies and processes that were not designed with these treatments in mind.
The new report explores five key trends in gene therapy approvals, industry challenges and ways biopharma can begin to address them.
Mike Ward, Global Head of Life Sciences and Healthcare Thought Leadership, Clarivate, said: “Even as the number of therapies in pipelines and available to patient begins to accelerate, the picture on market access and commercial launch for these products remains uncertain. To be successful, companies developing gene therapies will want to consider the patient journey as well as the market, competitive, regulatory and payer landscapes.”
Click below to share this article